<DOC>
	<DOCNO>NCT00240370</DOCNO>
	<brief_summary>The purpose study evaluate type 2 diabetic inadequate glycemic control metformin alone , similar , inferior , glycemic response treat combination muraglitazar metformin compare pioglitazone metformin .</brief_summary>
	<brief_title>A Study Evaluate Combining Metformin With Muraglitazar Pioglitazone Type 2 Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Type 2 diabetic HbA1c ≥7.0 % ≤10.0 % , currently receive stable dose metformin 1500 2550 mg/day least 6 week prior screen enrol study . Fasting Cpeptide ≥1.0 ng/mL BMI≤41 kg/m2 mean fast serum trig . ≤600 g/dL symptomatic type 2 diabetic &gt; 10 % weight loss 3 month prior study history diabetic ketoacidosis , hyperosmolar nonketotic coma , insulin therapy , inability take muraglitazar , pioglitazone , metformin accord investigator brochure label History MI ( myocardial infarction ) , coronary angioplasty bypass graft ( ) , valvular disease repair , unstable angina pectoris , transient ischemic attack ( TIA ) , cerebrovascular attack , cerebrovascular accident ( CVA ) within 6 month , congestive heart failure ( NYHA Class III IV , uncontrolled hypertension , history , renal disease , peripheral vascular disease ( PVD ) , pulmonary disease , gastrointestinal disease , active liver disease endocrine disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>